Everything you expect from cell line development – yet without the problems
Wherever glycosylation is a problem, moss is your solution. Moss has no core α-1,6 fucose to begin with. Any other glycans can be modified to the desired effect, be it by knocking certain genes out or inserting the necessary transferases. No allergens, more power. We are experts in moss glycodesign, “humanizing” the molecules’ glycostructure. We have demonstrated excellent organ uptake, even in clinical studies. Our “glyco platform” is just what you were hoping for.
Flexible genetic engineering
Moss is haploid by nature and boasts its very own pair of DNA scissors. Engineering its genome is easy. Make any changes you like, wherever you need them: change one nucleotide or a thousand, one site or many. We don’t even need markers to check the correct modifications, just PCR. The moss production system is based on an intact organism, not artificial cell cultures. This guarantees exceptionally reliable and stable modifications.
The lack of animal pathogens means antibiotics are not necessary. Not only does this ensure constant supply with no threat of contamination. It also eliminates the time and cost-consuming process of removing pathogens in the first place, and ticks another box for regulatory approval.
fusion toxin production
Moss can produce any desired toxin or toxin fusion protein, be it by natural resistance or by means of a genetically engineered, resistant platform. Moss cells hardly leak any toxins into the cytosol, but secrete them – making harvesting easy. Impossible in any other cells!
Moss can express proteins other culture systems can not
- Proteins that are inhibitive or toxic for mammalian cell cultures (CHO/SP20)
- Large proteins (> 200 kDa)
- Proteins with complex human glycosylation
Moss cells provide a highly robust production system
- Moss cells – like all plant cells – have a cell wall, making them more robust than mammalian cells
- Production process is stable in a wide range of pH and temperature
- Moss cells can be genetically modified by efficient homologous recombination. Engineered moss cells are genetically highly stable.
- High batch-to-batch stability
- Moss plant cells typically have higher success rates than other cell production systems
- Media contain mainly salts and glucose, contributing to stability and cost efficiency
- Moss cell-produced recombinant proteins have been used in clinical trials
Moss produces proteins cost-efficiently in bioreactors
- Moss cell cultures can be run in 500 l stirring bioreactors (potential for up to 2000 l)
- Moss has already generated yields of 200 mg/l in 500 l scale with demanding proteins (potential for g/l scale in the next 2–3 years)
- Moss offers a 4–5 times more efficient cell bank production (1000 vials per batch)
- No need for virus filtration/inactivation means costs for protein purification are up to 15–20 % lower
- Growth media costs are 5–10 times lower than for mammalian cell cultures
Moss delivers proteins for various sectors
- Monoclonal, glycoengineered antibodies for oncology
- Aglycosylated proteins > 20 kDa
- Biodefense enzymes
- Fusion toxins/toxins
- Recombinant vaccines
- LSD enzymes
|Product||Starting yield [mg/l]||Optimized yield [mg/l]||Year of production||
Titer (mg/l) in
current max scale
|Alpha galactosidase A||23||280||2018||60 (500 l)|
|Complement factor H||7||330||2020||350 (500 l)|